The laboratory blood cancer researchers at the University of Nottingham have been busy during lockdown in 2020. FOUR papers have been peer-reviewed and published. All of these publications include work or people who have been funded by the NLA. A summary of each follows:
• Bailey GD, Doolan L, Baskar A, Smith LC, Seedhouse CH. Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia. Scientific Reports 2020
This paper has identified a genetic phenomenon which occurs in 35% of patients with acute myeloid leukaemia. The work is a direct output from a Nottinghamshire Leukaemia Appeal Grant which funded Dr Graham Bailey who performed this project. Experiments are continuing to attempt to target this genetic abnormality as a treatment for the disease.
• Grundy M, Al-Kaisi F, Cull J, Williams C, Smith D, Seedhouse CH. A same day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3 mimetic targeting in multiple myeloma cells. EJHaem 2020.
There are many different drugs available to treat multiple myeloma, but clinicians do not always know the best ones to use. This publication describes a quick method using patient cells that provides information about whether a drug combination is effective in killing a particular patients myeloma cells. The Nottinghamshire Leukaemia Appeal provided funding for consumables to the laboratory where the work was performed and are now funding Dr Martin Grundy to continue this work.
• Alhuthali HM, Bradshaw TD, Lim KH, Tam KS, Seedhouse CH. The natural alkaloid Jerantinine B has activity in acute myeloid leukaemia cells through a mechanism involving c-Jun. BMC Cancer 2020.
This work examined whether a naturally occurring chemical would be a candidate for the treatment of acute myeloid leukaemia. The results are promising and have identified a cellular target of the new drug which is prevalent in leukaemia cells but not normal cells. The Nottinghamshire Leukaemia Appeal provided funding for consumables to the laboratory where the work was performed.
• Almasmoum H, Seedhouse C, Winkler GS. Frequent loss of BTG1 activity and impaired interactions with the Caf1 subunit of the Ccr4-Not deadenylase in non-Hodgkin lymphoma. Leukemia and Lymphoma 2020.
This paper describes the effects of a mutation, commonly found in patient with non-Hodgkins lymphoma. The more we know about the biological consequences of a mutation, the more likely we are to discover whether the mutation, which only occurs in the lymphoma cells, can be exploited in new therapies. The Nottinghamshire Leukaemia Appeal provided funding for consumables to the laboratory where some of this work was performed.